Clinical Trials on Marginal Zone B-Cell Lymphoma

Total 7682 results

National Cancer Institute (NCI)

Completed

Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Nodal Marginal Zone Lymphoma

United States
Enterome

Recruiting

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (SIDNEY)

Follicular Lymphoma | Marginal Zone Lymphoma

United States, Italy, Spain
University of Rochester

Terminated

A Phase II Study of Doxycycline in Relapsed NHL

Lymphoma, Follicular | Waldenstrom Macroglobulinemia | T-Cell Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma | Adult Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma Recurrent | Marginal Zone B-Cell Lymphoma | Malignant Lymphoma - Lymphoplasmacytic

United States
IGM Biosciences, Inc.
ADC Therapeutics S.A.

Active, not recruiting

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCL

United States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
BeiGene

Recruiting

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY)

Marginal Zone Lymphoma | Relapsed/Refractory Follicular Lymphoma

United States, Italy, Spain, China, United Kingdom, Australia, Israel, Korea, Republic of, France, Brazil, Ireland, Czechia, Romania, Argentina, Puerto Rico, Austria
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)

Relapsed/Refractory Follicular Lymphoma | Marginal Zone Lymphoma (MZL)

Korea, Republic of, Australia, France, Spain, Malaysia, Taiwan, Italy, Poland, United States, Thailand, United Kingdom, Belgium, Turkey, Czechia
Incyte Corporation

Withdrawn

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Marginal Zone Lymphoma (MZL) | Follicular Lymphoma ( FL)
HaEmek Medical Center, Israel

Completed

Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease (B-RAF V600E)

Splenic Marginal Zone Lymphoma | Hairy Cell Leukemia
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

Recruiting

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | MALT Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Indolent Lymphoma | Refractory B-Cell Lymphoma

United States, Australia, China
MEI Pharma, Inc.
Kyowa Kirin, Inc.

Terminated

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Follicular Lymphoma (FL)

United States, France, Spain, Korea, Republic of, United Kingdom, Belgium, Japan, Taiwan, Australia, Poland, Italy, Canada, Georgia, Greece, Hungary, Netherlands, New Zealand, Serbia, Turkey
MEI Pharma, Inc.

Terminated

Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Follicular Lymphoma (FL)

United States, Spain, Korea, Republic of, Belgium, Taiwan, Germany, France, Italy, Australia, Poland, New Zealand, United Kingdom, Austria, Switzerland
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Dana-Farber Cancer Institute
Eli Lilly and Company

Withdrawn

ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia
Lymphoma Study Association

Completed

Lenalidomide and R-CHOP in B-cell Lymphoma (R2CHOP-1)

Lymphoma, Large B-Cell, Diffuse | Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma

France
Kite, A Gilead Company

Active, not recruiting

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)

Follicular Lymphoma | Marginal Zone Lymphoma | Indolent Non-Hodgkin Lymphoma

United States, France
National Cancer Institute (NCI)

Completed

CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Thomas Jefferson University
National Cancer Institute (NCI)

Recruiting

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Indolent Adult Non-Hodgkin...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Small Lymphocytic Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Extranodal Marginal Zone Lymphoma of Mucosa-Associated... and other conditions

United States
Polish Lymphoma Research Group

Completed

First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. (PLRG4)

Follicular Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma

Poland
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade... and other conditions

United States
Mayo Clinic

Recruiting

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Sunesis Pharmaceuticals

Terminated

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Lymphoplasmacytoid Lymphoma

United States
TG Therapeutics, Inc.

Terminated

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Non-Hodgkins Lymphoma | Small Lymphocytic Lymphoma | B-cell Lymphomas

United States
Gilead Sciences

Completed

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas (DELTA)

Follicular Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma

United States, United Kingdom, Italy, Germany, Poland, France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment

Marginal Zone Lymphoma of Ocular Adnexal

Italy
Reid Merryman, MD
Genentech, Inc.

Recruiting

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma | Indolent Non-hodgkin Lymphoma

United States
Epizyme, Inc.

Completed

Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Advanced Solid Tumor | Diffuse Large B Cell Lymphoma | Primary Mediastinal Lymphoma

United States
National Cancer Centre, Singapore
Samsung Medical Center; Singapore General Hospital

Terminated

Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Lymphoma, B-Cell, Marginal Zone

Singapore
University Hospital, Strasbourg, France

Recruiting

B-cell Chronic Lymphoid Malignancies Markers (MALYZOMA-II)

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Hairy Cell Leukemia | Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia

France
M.D. Anderson Cancer Center

Recruiting

A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma

Lymphoma

United States
Incyte Corporation

Active, not recruiting

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Lymphoma

Belgium, United States, France, Israel, Italy, United Kingdom, Germany, Spain, Poland, Australia, Argentina, Denmark
Andres J. M. Ferreri

Completed

Salvage Therapy With High Dose Oral Clarithromycin in Relapsed or Refractory Extranodal Marginal Zone Lymphoma (HD-K)

Lymphoma

Italy
BeiGene

Recruiting

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Relapsed Follicular Lymphoma | Refractory Small Lymphocytic Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Diffuse Large B-cell Lymphoma | Transformed Non-Hodgkin Lymphoma | Relapsed... and other conditions

China, Australia
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditions

United States
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Immunoblastic... and other conditions

United States
University Hospital Muenster
International Lymphoma Radiation Oncology Group (ILROG)

Recruiting

ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma

Follicular Lymphoma (Gastric or Duodenal) | Marginal Zone Lymphoma (Gastric or Duodenal)

Germany
Fate Therapeutics

Withdrawn

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Transformed Indolent Non-Hodgkin's Lymphoma
Genmab
AbbVie

Active, not recruiting

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL (EPCORE™ NHL-3)

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma

Japan
Poseida Therapeutics, Inc.
Roche-Genentech

Recruiting

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL)

United States
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

MZL

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Recurrent Diffuse Large B-Cell Lymphoma | CD20 Positive | T-Cell Non-Hodgkin Lymphoma

United States
Ruijin Hospital
The First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaborators

Not yet recruiting

A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types

Lymphoma | Marginal Zone Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Mucosa-Associated Lymphoid Tissue Lymphoma | Intravascular Large B-Cell Lymphoma | Extranodal Lymphoma | NK/T-Cell Lymphoma, Nasal and Nasal-Type

China
MEI Pharma, Inc.

Recruiting

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Acute Myeloid Leukemia (AML) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL)

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Splenic Marginal Zone Lymphoma | Anaplastic Large Cell Lymphoma | Recurrent Adult Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent... and other conditions

United States
Genmab
AbbVie

Terminated

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma

United States, Spain, Netherlands, Belgium, France, Denmark
Epizyme, Inc.

Completed

Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors

Follicular Lymphoma | Marginal Zone Lymphoma | Advanced Solid Tumors | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal Lymphoma

United Kingdom

Clinical Trials on Marginal Zone B-Cell Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations